Celldex Therapeutics Announces Initiation Of Randomized Phase 2 Clinical Trial Of CDX-1307 In Front Line Bladder Cancer

Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform.